NID1 Antibody

Introduction to NID1 Antibody

NID1 antibodies are immunoglobulins specifically designed to target Nidogen-1 (also known as Entactin), a critical glycoprotein component of basement membranes. These antibodies have been developed in various formats, including monoclonal and polyclonal variants, with different conjugations to serve various research and potential therapeutic purposes. NID1 antibodies are available from multiple commercial suppliers and have been increasingly utilized in cancer research due to the emerging role of Nidogen-1 in tumor development and progression .

Nidogen-1 serves as a major linking component of basement membranes, functioning as a 150 kDa secreted monomeric glycoprotein. Its structural importance in connecting various basement membrane components makes it an attractive target for therapeutic intervention in diseases where basement membrane disruption plays a significant role .

Structure and Properties of Nidogen-1 (Target Protein)

Nidogen-1 is a highly conserved structural component of the extracellular matrix (ECM). As a 150 kDa glycoprotein, it functions primarily by interacting with different basement membrane proteins to form a stabilized meshwork . The protein is encoded by the NID1 gene in humans and may also be known under alternative names such as Entactin, NID, NID-1, and enactin .

Functional Domains of Nidogen-1

The human Nidogen-1 protein spans from Leu29 to Lys1114 (with a noted Gln1113Arg variation) according to accession number AAH45606 . One of the critical regions of the protein is the G2 domain, which has been specifically targeted in the development of neutralizing antibodies for therapeutic purposes . The importance of this particular domain lies in its involvement in protein-protein interactions within the basement membrane structure.

Types of NID1 Antibodies

The commercial landscape offers various types of NID1 antibodies designed for different experimental and potential clinical applications. These antibodies vary in their host organisms, clonality, and conjugation status.

Host Organisms and Clonality

NID1 antibodies are commonly produced in mice and rabbits. For example, monoclonal anti-NID1 antibody clone 1G3 is mouse-derived, while the E9J3L clone is rabbit-derived . Both monoclonal and polyclonal variants are available, each offering distinct advantages depending on the application requirements.

Applications of NID1 Antibodies

NID1 antibodies have been utilized in various experimental techniques, offering insights into both fundamental biology and pathological conditions.

Laboratory Applications

The primary laboratory applications of NID1 antibodies include:

1. Western Blotting (WB): Typically used at dilutions of 1:1000, allowing detection of the 150 kDa NID1 protein

2. Immunohistochemistry (IHC): Both paraffin-embedded (IHC-p) and frozen sections (IHC-fr)

3. Enzyme-Linked Immunosorbent Assay (ELISA): Particularly effective with conjugated antibody variants

4. Immunocytochemistry (ICC) and Immunofluorescence (IF): For cellular localization studies

5. Simple Western™: Automated capillary-based systems at dilutions of 1:50-1:250

Research Applications in Disease Studies

Beyond standard laboratory techniques, NID1 antibodies have been instrumental in studying the role of Nidogen-1 in various pathological conditions, particularly in cancer research. Specific applications include:

1. Monitoring NID1 expression levels in different cancer types

2. Identifying NID1 as a potential biomarker for cancer progression and metastasis

3. Therapeutic targeting of NID1 to inhibit tumor growth and metastasis

Research Findings on NID1 Antibodies in Cancer Treatment

Recent research has revealed significant potential for NID1 antibodies in cancer therapy, with promising results across multiple cancer types.

Development of Neutralizing NID1 Antibody

A groundbreaking study published in 2025 reported the development of a monoclonal neutralizing antibody specifically targeting the G2 region of NID1 . This antibody was developed using hybridoma technology and demonstrated remarkable efficacy against various human cancer cells.

Therapeutic Effects on Multiple Cancer Types

The therapeutic potential of the NID1 neutralizing antibody has been demonstrated across several cancer types:

Hepatocellular Carcinoma (HCC)

In HCC models, treatment with the anti-NID1 antibody resulted in:

• Decreased NID1 levels in HCC cells

• Inhibited colony-forming ability of metastatic cells

• Significantly hampered tumor growth in an orthotopic liver implantation model

• Reduced tumor proliferation as evidenced by Ki67 staining

Lung Cancer, Breast Cancer, and Nasopharyngeal Carcinoma (NPC)

Similar therapeutic effects were observed in lung cancer, breast cancer, and NPC models:

• Reduced cellular NID1 levels

• Significantly decreased colony-forming, migration, and invasion abilities

• Delayed tumor development in subcutaneous mouse models

• Reduced tumor volume and weight

• Decreased Ki67-positive cells in excised tumors

Clinical Relevance of NID1 in Cancer

The clinical significance of NID1 in cancer has been well-documented across multiple cancer types, as summarized in the following table adapted from recent research:

These findings highlight the potential of NID1 as a therapeutic target across a wide range of cancer types .

Mechanism of Action

The therapeutic efficacy of NID1 neutralizing antibody appears to be mediated through multiple mechanisms.

Molecular Mechanisms

Mechanistic studies have revealed that treatment with NID1 neutralizing antibody leads to the deregulation of the hypoxia-inducible factor-1 (HIF-1α) pathway in cancer cells . This pathway plays a crucial role in cancer cell adaptation to hypoxic conditions, angiogenesis, and metastasis.

Effects on Tumor Microenvironment

As a basement membrane component, NID1 contributes to the structural integrity of the extracellular matrix. By targeting NID1, the antibody may disrupt the tumor microenvironment, affecting cell adhesion, migration, and invasion - all critical processes in cancer progression and metastasis .

Potential for Targeted Therapy

The consistent upregulation of NID1 across multiple cancer types suggests its potential as a pan-cancer therapeutic target. The development of a commercial anti-NID1 neutralizing antibody could provide a new treatment option for patients with various malignancies .

Combinatorial Approaches

Future research could explore the combination of NID1 antibodies with established cancer therapies, such as chemotherapy, radiation therapy, or immune checkpoint inhibitors, to enhance therapeutic efficacy.

Diagnostic Applications

Beyond therapeutic applications, NID1 antibodies may serve as valuable diagnostic tools. The elevated levels of NID1 in cancer patient sera and tissues suggest its potential as a biomarker for cancer detection and monitoring .